Vanda Pharmaceuticals Files 8-K
Ticker: VNDA · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Vanda Pharma filed an 8-K on Oct 1st, likely with important company updates.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on October 1, 2025, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates that Vanda Pharmaceuticals Inc. has made a regulatory submission to the SEC, which could contain important updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard procedural document (8-K) without immediate negative or positive financial implications disclosed in the provided text.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- 20037 (location) — ZIP code
- 20251001 (date) — Conformed period of report
FAQ
What specific events are being reported in this 8-K filing by Vanda Pharmaceuticals Inc.?
The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of these events.
When was this 8-K filing submitted by Vanda Pharmaceuticals Inc.?
The filing was submitted on October 1, 2025, which is also the date of the earliest event reported.
What is Vanda Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Vanda Pharmaceuticals Inc.'s IRS Employer Identification Number (EIN)?
Vanda Pharmaceuticals Inc.'s IRS Employer Identification Number is 03-0491827.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-10-01 17:10:10
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20251001.htm (8-K) — 30KB
- vnda8-k1012025exhibit991.htm (EX-99.1) — 14KB
- vandaq32019earningsca_imaga.jpg (GRAPHIC) — 48KB
- 0001628280-25-043489.txt ( ) — 232KB
- vnda-20251001.xsd (EX-101.SCH) — 2KB
- vnda-20251001_lab.xml (EX-101.LAB) — 22KB
- vnda-20251001_pre.xml (EX-101.PRE) — 13KB
- vnda-20251001_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 1, 2025, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release announcing that it had reached a collaborative framework with the U.S. Food and Drug Administration for the resolution of certain disputes regarding Vanda's drugs, HETLIOZ (tasimelteon) and tradipitant. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated October 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 1, 2025 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary